Literature DB >> 4058515

Bioavailability of oral physostigmine.

R Whelpton, P Hurst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4058515     DOI： 10.1056/NEJM198511143132016

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

2.  Pharmacokinetics of physostigmine in man following a single application of a transdermal system.

Authors:  K Walter; M Müller; M F Barkworth; A V Nieciecki; F Stanislaus
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

3.  Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

Authors:  J R Atack; I Litvan; L J Thal; C May; S I Rapoport; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

Review 4.  Current advances in transdermal delivery of drugs for Alzheimer's disease.

Authors:  Thuy Trang Nguyen; Vo Van Giau; Tuong Kha Vo
Journal:  Indian J Pharmacol       Date:  2017 Mar-Apr       Impact factor: 1.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.